Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Epidermal Growth Factor Receptor (EGFR) is a type-I transmembrane protein with tyrosine kinase activity.
• EGFR plays a critical role in cell growth, migration, and differentiation, and its overexpression is linked to tumor progression and drug resistance in various cancers, including breast cancer.

Purpose of the Study:

• To review the critical role of EGFR in breast cancer progression.
• To enumerate approaches for inhibiting aggressive breast cancers by suppressing downstream pathways.
• To illustrate the mechanisms of action of potential molecules and FDA-approved drugs targeting EGFR.

Main Methods:

• Literature review of EGFR's role in breast cancer.
• Analysis of EGFR overexpression in various cancers.
• Examination of EGFR inhibition strategies and drug mechanisms.

Main Results:

• EGFR overexpression drives cell division, invasion, and survival, contributing to breast cancer progression and resistance.
• EGFR inhibition modulates chemosensitivity in breast cancer stem cells.
• FDA-approved EGFR inhibitors (Lapatinib, Neratinib, Trastuzumab) are available for clinical use.

Conclusions:

• EGFR is a significant therapeutic target for mitigating aggressive breast cancers.
• Targeting downstream pathways of EGFR offers potential for novel breast cancer treatments.
• Understanding EGFR's mechanisms is key to developing effective breast cancer therapies.